Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT-2: Phase 3 study of KarXT for psychosis associated with Alzheimer's disease
CTR20241739Phase 3Active
- Sponsor
- Karuna Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline in Alzheimer's disease (AD), sponsored by Karuna Therapeutics. Started Sep 2024; status: active.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20241739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241739.